Intravitreal implant, ganciclovir

Other CMV infections IV Initially, 10mg/kg/dayindivideddosesql2hfor 14-21 days, then 5 mg/kg/day as a single daily dose. Maintenance 1000 mg 3 times a day or 500 mg q3h (6 times a day). Intravitreal implant 1 implant q6-9mo plus oral ganciclovir. Dosage in renal impairment Dosage and frequency are modified based on creatinine clearance. 

A ganciclovir intravitreal implant (Vitrasert, Chiron Vision, Claremont, CA) that has been developed provides release of 4.5 mg ganciclovir from a PVA and ethyl-vinyl-acetone polymer pellet at approximately... 

Vitrasert Ganciclovir Bausch Lomb Marketed product Cytomegalovirus Intravitreal implant... 

The success of intravitreal implants, such as achieved with ganciclovir, has renewed interest in developing an intravitreal corticosteroid implant to further enhance the intravitreal route of administration, thus reducing the need for multiple injections. Bausch and Lomb and Control Delivery Systems have developed an intravitreal implant that can deliver the corticosteroid fluocinolone acetonide (Retrisert) to posterior eye tissue for up to 3 years. The implant, which was approved in 2005 by the U.S. Food and DrugAdministration (FDA), delivers 0.59 or 2.1 mg of fluocinolone acetonide. The long-term ocular side effects of this device are unknown at this time. 

Ganciclovir Intravenous administration Intravitreal injection Intravitreal implant Oral administration (valganciclovir) Primary toxicity = neutropenia... 

An intravitreal implant device (Vitrasert, Bausch Lomb Surgical, San Dimas, CA, USA) consists of a 6-mg pellet of ganciclovir compressed into a 2.5-mm disk, coated with polyvinyl alcohol on all sides, and then coated with ethylvinyl alcohol on all sides except the top. It releases ganciclovir at a constant rate into the vitreous cavity after implantation through the pars plana under local anesthesia. Perhaps the greatest benefit of intravitreal... 

Figure 3 The ganciclovir intravitreal implant is noted behind the lens and iris in the infer-otemporal quadrant.

Ganciclovir (cytovene) (vetrasert) Intravenous, oral, Intravitreal implant Cytomegalovirus retinitis... 

Ganciclovir Vitrasert Intravitreal implant Poly(ethylene -CO-vinyl alcohol) Viral retini-ties (inflammation of retina) In market... 

Dillon B, Kamal A, Leen C. Intravitreal sustained-released ganciclovir implantation to control cytomegalovirus retinitis in AlDS.lntJ STD AIDS 1998 9 227-230. 

Yasukawa T, Kimura H, Kunou N, et al. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 2000 238 186-190. 

Duker JS, Robinson M, Anand R, Ashton P. Initial experience with an eight month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surg Lasers 1995 26 442-448. 

Martin D, Kupperman B, Wolitz R, Palestine C, Robinson C. Combined oral ganciclovir and intravitreal ganciclovir implant for treatment of patients with cytomegalovirus (CMV) retinitis a randomized controlled study. In 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Abstract LB-9. 

Intravitreal ganciclovir injections have been used in some patients, and an intraocular sustained-release ganciclovir implant (vitrasert) is more effective than systemic dosing in suppressing retinitis progression. 

---